We are live on ! Find out more
Aberdeen Group

Aberdeen Group Portfolio holdings

AUM $61.9B
1-Year Est. Return 29.81%
This Fund
S&P 500
This Quarter Est. Return
+13.55%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
AUM
$58.8B
AUM Growth
+$7.51B
Cap. Flow
+$1.9B
Cap. Flow %
3.23%
Top 10 Hldgs %
34.73%
Holding
979
New
37
Increased
681
Reduced
201
Closed
28

Top Buys

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$154M
2
SPOT icon
Spotify
SPOT
+$132M
3
NVDA icon
NVIDIA
NVDA
+$124M
4
MSFT icon
Microsoft
MSFT
+$107M
5
META icon
Meta Platforms (Facebook)
META
+$71.3M

Sector Composition

Rank Sector Weight
1 Technology 32.3%
2 Healthcare 12.75%
3 Consumer Discretionary 11.56%
4 Financials 10.82%
5 Communication Services 9.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GEN icon
526
Gen Digital
GEN
$15.6B
$13.5M 0.02%
461,713
+13,827
+3% +$378K
FANG icon
527
Diamondback Energy
FANG
$57.6B
$13.5M 0.02%
98,547
+4,017
+4% +$557K
IMVT icon
528
Immunovant
IMVT
$8.09B
$13.5M 0.02%
844,705
+25,228
+3% +$381K
AEE icon
529
Ameren
AEE
$31.5B
$13.5M 0.02%
140,640
+11,658
+9% +$1.13M
IDA icon
530
Idacorp
IDA
$8.23B
$13.4M 0.02%
115,978
+24,762
+27% +$2.87M
MEDP icon
531
Medpace
MEDP
$16.8B
$13.4M 0.02%
42,556
-21,553
-34% -$6.47M
NAMS icon
532
NewAmsterdam Pharma
NAMS
$3.47B
$13.3M 0.02%
735,032
+358,169
+95% +$6.53M
CHRW icon
533
C.H. Robinson
CHRW
$22B
$13.3M 0.02%
138,688
+24,587
+22% +$2.3M
TVTX icon
534
Travere Therapeutics
TVTX
$5.33B
$13.3M 0.02%
896,594
+416,225
+87% +$6.9M
EWT icon
535
iShares MSCI Taiwan ETF
EWT
$10B
$13.2M 0.02%
230,973
+89,367
+63% +$4.57M
BAX icon
536
Baxter International
BAX
$11.6B
$13.2M 0.02%
437,321
+53,257
+14% +$1.61M
MDB icon
537
MongoDB
MDB
$24B
$13.1M 0.02%
62,570
+2,503
+4% +$463K
DOW icon
538
Dow Inc
DOW
$21.6B
$13.1M 0.02%
488,920
+20,126
+4% +$585K
DTE icon
539
DTE Energy
DTE
$31.1B
$12.9M 0.02%
97,536
+8,550
+10% +$1.15M
KRC icon
540
Kilroy Realty
KRC
$4.58B
$12.8M 0.02%
372,167
+336,953
+957% +$11M
IBN icon
541
ICICI Bank
IBN
$106B
$12.7M 0.02%
378,223
+67,937
+22% +$2.25M
CDTX
542
DELISTED
Cidara Therapeutics
CDTX
$12.7M 0.02%
259,916
+139,037
+115% +$3.34M
HAL icon
543
Halliburton
HAL
$27.9B
$12.6M 0.02%
613,025
+21,736
+4% +$456K
DNLI icon
544
Denali Therapeutics
DNLI
$3.67B
$12.6M 0.02%
902,751
+142,936
+19% +$2.01M
WGS icon
545
GeneDx Holdings
WGS
$1.75B
$12.6M 0.02%
+136,732
New +$10.7M
NI icon
546
NiSource
NI
$22.4B
$12.5M 0.02%
310,284
+48,533
+19% +$1.9M
MGY icon
547
Magnolia Oil & Gas
MGY
$5.83B
$12.3M 0.02%
546,267
-74,464
-12% -$1.65M
MKL icon
548
Markel Group
MKL
$25B
$12.3M 0.02%
6,135
+326
+6% +$611K
AAON icon
549
Aaon
AAON
$8.41B
$12.2M 0.02%
165,897
+136,288
+460% +$11.9M
RIO icon
550
Rio Tinto
RIO
$148B
$12.2M 0.02%
208,700
+6,600
+3% +$390K

Similar funds

Aberdeen Group's Q2 2025 Portfolio in Review

As of Q2 2025, Aberdeen Group held 979 positions worth $58.8B, up 15% from $51.3B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Aberdeen Group deployed $1.9B of net new capital in Q2 2025, opening 37 new positions and adding to 681 existing holdings. Its largest new stake was On Holding: 756,875 shares worth $39.4M.

By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 29% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was Southern Copper, an estimated $61.4M trimmed.

  • Aberdeen Group's largest Q2 2025 buy was On Holding: 756,875 shares worth $39.4M.
  • Aberdeen Group added most to Apple in Q2 2025, an estimated $154M increase.
  • Aberdeen Group's biggest Q2 2025 reduction was Southern Copper, cutting an estimated $61.4M.
  • Aberdeen Group fully exited Globant in Q2 2025, selling an estimated $60.5M.
  • Aberdeen Group's ten largest holdings make up 35% of its $58.8B portfolio in Q2 2025.
  • Aberdeen Group opened 37 new positions and closed 28 in Q2 2025.
  • Aberdeen Group's portfolio value rose 15% quarter-over-quarter to $58.8B.

Based on Aberdeen Group's 13F filing for Q2 2025, filed 24 Jul 2025.